Fibro-Vein, 5 mg/ml 2 ml 5 pcs

The drug Fibro-Vein has a venosclerosing effect, it has surface-active properties.

Injection of the drug into the lumen of the varicose vein causes irritation of the vessel intima with subsequent fibrosis, adhesion of the vein walls and its obliteration.

It has no noticeable effect on the functions of the central and peripheral nervous system, cardiovascular system, renal and hepatic function, biochemical parameters of blood and urine.

In contact with perivascular tissues it has an irritating effect.

Indications

Treatment of uncomplicated, moderately severe varicose veins of the lower extremities using compression sclerotherapy. Treatment of telangiectasia.

Pharmacological effect

The drug Fibro-Vayne has a venosclerosing effect and has surface-active properties.

When the drug is administered into the lumen of a varicose vein, irritation of the intima of the vessel occurs, followed by fibrosis, adhesion of the vein walls and its obliteration.

Does not have a noticeable effect on the functions of the central and peripheral nervous system, cardiovascular system, kidney and liver function, biochemical parameters of blood and urine.

If it gets into perivascular tissue, it has an irritating effect.

Special instructions

1. Fibro-Vayne should be used by doctors who are proficient in sclerotherapy techniques. It is necessary to correctly assess valvular insufficiency and the condition of the deep veins.
2. Sclerosis of veins is carried out with caution with absolute confidence in the patency of the deep and communicative veins of the lower extremities.
3. Before starting treatment, it is necessary to know the patient’s allergic history. You can administer 0.25-0.5 ml of Fibro-Vein to the patient 24 hours before the start of treatment to identify a possible allergic reaction.
4. Care must be taken when treating patients with peripheral atherosclerosis and Buerger’s disease.
5. Particular care must be taken to inject the drug into the area above and behind the medial malleolus, because there is the posterior tibial artery.
6. Avoid extravasal (paravenous) and intra-arterial administration.
7. Do not use the drug in case of precipitation or change in color of the solution.
8. When the temperature decreases, a precipitate may form in the solution, which dissolves when heated.
9. To prevent relapses after treatment, patients are recommended to wear elastic stockings.

Active ingredient

Sodium tetradecyl sulfate

Composition

1 ml contains:

Active ingredient:

sodium tetradecyl sulfate 5 mg.

Excipients:

benzyl alcohol,

sodium phosphate disubstituted,

potassium phosphate monosubstituted,

water for injections.

Contraindications

Hypersensitivity to the drug Fibro-Vayne;
bronchial asthma;
severe liver and kidney diseases;
acute thrombosis and thrombophlebitis;
soft tissue infection;
infectious diseases;
obliterating peripheral arteriosclerosis;
diabetic angiopathy;
pregnancy and lactation;
after treatment for alcoholism;
obesity;
taking oral contraceptives;
sedentary lifestyle;
varicose veins, as a result of a tumor of the abdominal cavity and pelvis;
heart defects requiring surgery;
extensive and pronounced varicose veins (including deep veins) with valve insufficiency; phlebosclerosis;
fever;
toxic hyperthyroidism;
oncological diseases;
acute infections;
tuberculosis;
sepsis;
violation of the cellular composition of the blood;
acute respiratory or skin diseases;
general diseases requiring bed rest, heart disease with symptoms of decompensation.

Side Effects

During the administration of the drug, especially during the first treatment session, dizziness, headache, nausea and increased sweating may occur.

When administering the drug, a burning sensation and slight pain at the injection site are noted.

If the drug gets under the skin, hyperpigmentation, infiltration and skin necrosis may develop.

Allergic reactions (urticaria, rash, anaphylactic shock) occur rarely.

Local reactions: intravaricose hematoma at the injection site, ascending phlebitis with or without accompanying periphlebitis.

Systemic reactions: bronchospasm, fever, pulmonary vein thrombosis.

In case of accidental intra-arterial injection – obliteration of the afferent vessel (up to the need for amputation of a limb), embolism (even 4 months after the procedure); with paravenous – the development of soft tissue necrosis.

Interaction

Not known. Pharmaceutically incompatible with heparin. It is not recommended to combine with oral contraceptives.

Storage conditions

In a place protected from light, at temperatures below 25 °C

Shelf life

3 years

Manufacturer

Siegfried Hameln GmbH, Germany